{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:57:01Z","timestamp":1793127421073,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The research funding of Nanjing Medical University and the research funding of the Jiangsu Province","award":["20182020"],"award-info":[{"award-number":["20182020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-025-01891-3","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T06:01:12Z","timestamp":1748498472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SERPINA1 methylation as a novel diagnostic marker for early-stage papillary thyroid carcinoma via MAPK6-AKT\/mTOR pathway"],"prefix":"10.1186","volume":"17","author":[{"given":"Junjie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"10061","key":"1891_CR1","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783\u201395.","journal-title":"Lancet"},{"issue":"5","key":"1891_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MED.0000000000000359","volume":"24","author":"BR Roman","year":"2017","unstructured":"Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017;24(5):332\u20136.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"1891_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.surg.2019.03.040","volume":"167","author":"B Saravana-Bawan","year":"2020","unstructured":"Saravana-Bawan B, et al. Active surveillance of low-risk papillary thyroid cancer: a meta-analysis. Surgery. 2020;167(1):46\u201355.","journal-title":"Surgery"},{"issue":"3","key":"1891_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/hed.26598","volume":"43","author":"T Todsen","year":"2021","unstructured":"Todsen T, et al. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules. Head Neck. 2021;43(3):1009\u201313.","journal-title":"Head Neck"},{"issue":"11","key":"1891_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2017.0500","volume":"27","author":"ES Cibas","year":"2017","unstructured":"Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341\u20136.","journal-title":"Thyroid"},{"issue":"5","key":"1891_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/PAP.0b013e3182666398","volume":"19","author":"LQ Wong","year":"2012","unstructured":"Wong LQ, Baloch ZW. Analysis of the bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes. Adv Anat Pathol. 2012;19(5):313\u20139.","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"1891_CR7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/his.14099","volume":"76","author":"E Provenzano","year":"2020","unstructured":"Provenzano E, et al. The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. Histopathology. 2020;76(7):942\u20139.","journal-title":"Histopathology"},{"issue":"1","key":"1891_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jamaoncol.2020.5935","volume":"7","author":"MJ Livhits","year":"2021","unstructured":"Livhits MJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol. 2021;7(1):70\u20137.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1891_CR9","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1210\/clinem\/dgab304","volume":"106","author":"MI Hu","year":"2021","unstructured":"Hu MI, et al. Afirma genomic sequencing classifier and xpression atlas molecular findings in consecutive Bethesda III-VI thyroid nodules. J Clin Endocrinol Metab. 2021;106(8):2198\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1891_CR10","doi-asserted-by":"publisher","first-page":"R415","DOI":"10.1530\/ERC-19-0093","volume":"26","author":"C Zafon","year":"2019","unstructured":"Zafon C, et al. DNA methylation in thyroid cancer. Endocr Relat Cancer. 2019;26(7):R415\u201339.","journal-title":"Endocr Relat Cancer"},{"key":"1891_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","volume":"70","author":"M Kulis","year":"2010","unstructured":"Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27\u201356.","journal-title":"Adv Genet"},{"issue":"3","key":"1891_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/cells9030624","volume":"9","author":"V Const\u00e2ncio","year":"2020","unstructured":"Const\u00e2ncio V, et al. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells. 2020;9(3):624. https:\/\/doi.org\/10.3390\/cells9030624.","journal-title":"Cells"},{"issue":"2","key":"1891_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/cyt.12248","volume":"27","author":"H Chang","year":"2016","unstructured":"Chang H, et al. DNA methylation analysis for the diagnosis of thyroid nodules - a pilot study with reference to BRAF(V) (600E) mutation and cytopathology results. Cytopathology. 2016;27(2):122\u201330.","journal-title":"Cytopathology"},{"issue":"1","key":"1891_CR14","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","volume":"13","author":"P Zhang","year":"2022","unstructured":"Zhang P, et al. Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors. Nat Commun. 2022;13(1):1588.","journal-title":"Nat Commun"},{"issue":"15","key":"1891_CR15","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.7150\/thno.35219","volume":"9","author":"X Su","year":"2019","unstructured":"Su X, et al. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK\/ERK and PI3K\/AKT pathways via distinct mechanisms. Theranostics. 2019;9(15):4461\u201373.","journal-title":"Theranostics"},{"key":"1891_CR16","doi-asserted-by":"publisher","first-page":"16051","DOI":"10.1038\/nrdp.2016.51","volume":"2","author":"CM Greene","year":"2016","unstructured":"Greene CM, et al. alpha1-Antitrypsin deficiency. Nat Rev Dis Primers. 2016;2:16051.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1891_CR17","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1007\/s13277-015-3163-2","volume":"36","author":"J Yang","year":"2015","unstructured":"Yang J, et al. Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer. Tumour Biol. 2015;36(7):5109\u201318.","journal-title":"Tumour Biol"},{"issue":"19","key":"1891_CR18","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.3390\/ijms221910560","volume":"22","author":"Z Rabekova","year":"2021","unstructured":"Rabekova Z, et al. Alpha-1 antitrypsin and hepatocellular carcinoma in liver cirrhosis: SERPINA1 MZ or MS genotype carriage decreases the risk. Int J Mol Sci. 2021;22(19):10560. https:\/\/doi.org\/10.3390\/ijms221910560.","journal-title":"Int J Mol Sci"},{"key":"1891_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.2147\/COPD.S368543","volume":"17","author":"LY Zhang","year":"2022","unstructured":"Zhang LY, et al. SERPINA1 methylation levels are associated with lung cancer development in male patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2022;17:2117\u201325.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"1891_CR20","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/ERC-17-0453","volume":"25","author":"L Lamartina","year":"2018","unstructured":"Lamartina L, et al. 8th edition of the AJCC\/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr Relat Cancer. 2018;25(3):L7\u201311.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1891_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/carcin\/bgx004","volume":"38","author":"R Yang","year":"2017","unstructured":"Yang R, et al. The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies. Carcinogenesis. 2017;38(3):312\u201320.","journal-title":"Carcinogenesis"},{"key":"1891_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-4939-7033-9_17","volume":"1615","author":"JS Lin","year":"2017","unstructured":"Lin JS, Lai EM. Protein-protein interactions: co-immunoprecipitation. Methods Mol Biol. 2017;1615:211\u20139.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"1891_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"key":"1891_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi6439","author":"Q Cai","year":"2021","unstructured":"Cai Q, et al. MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abi6439.","journal-title":"Sci Adv"},{"issue":"8","key":"1891_CR25","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.bbamcr.2006.11.001","volume":"1773","author":"P Coulombe","year":"2007","unstructured":"Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim Biophys Acta. 2007;1773(8):1376\u201387.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1891_CR26","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1172\/JCI97712","volume":"129","author":"W Wang","year":"2019","unstructured":"Wang W, et al. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT\/mTOR signaling. J Clin Invest. 2019;129(3):1015\u201329.","journal-title":"J Clin Invest"},{"issue":"9","key":"1891_CR27","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1210\/clinem\/dgaa322","volume":"105","author":"G Grani","year":"2020","unstructured":"Grani G, et al. Contemporary thyroid nodule evaluation and management. J Clin Endocrinol Metab. 2020;105(9):2869\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1891_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2478\/raon-2018-0039","volume":"52","author":"M Mileva","year":"2018","unstructured":"Mileva M, et al. Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III. Radiol Oncol. 2018;52(4):370\u20136.","journal-title":"Radiol Oncol"},{"issue":"2","key":"1891_CR29","first-page":"268","volume":"40","author":"X Lai","year":"2020","unstructured":"Lai X, et al. Detection rate of thyroid nodules in routine health check-up and its influencing factors: a 10-year survey of 309 576 cases. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(2):268\u201373.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"11","key":"1891_CR30","first-page":"1311","volume":"52","author":"Y Lei","year":"2022","unstructured":"Lei Y, et al. Conventional papillary thyroid carcinoma with intraglandular lymphatic dissemination shows more aggressive features. Jpn J Clin Oncol. 2022;52(11):1311\u201320.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"1891_CR31","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cam4.3743","volume":"10","author":"Z Wu","year":"2021","unstructured":"Wu Z, et al. Which is preferred for initial treatment of papillary thyroid cancer, total thyroidectomy or lobotomy? Cancer Med. 2021;10(5):1614\u201322.","journal-title":"Cancer Med"},{"key":"1891_CR32","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1016\/j.clinsp.2022.100022","volume":"77","author":"MG Rodrigues","year":"2022","unstructured":"Rodrigues MG, et al. Incidental thyroid carcinoma: Correlation between FNAB cytology and pathological examination in 1093 cases. Clinics. 2022;77:100022. https:\/\/doi.org\/10.1016\/j.clinsp.2022.100022.","journal-title":"Clinics"},{"key":"1891_CR33","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.6061\/clinics\/2018\/e370","volume":"73","author":"L Mosca","year":"2018","unstructured":"Mosca L, et al. Malignancy rates for Bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB). Clinics. 2018;73:e370. https:\/\/doi.org\/10.6061\/clinics\/2018\/e370.","journal-title":"Clinics"},{"issue":"7","key":"1891_CR34","first-page":"e16708","volume":"13","author":"NA Hacim","year":"2021","unstructured":"Hacim NA, et al. Impact of ultrasonographic features for thyroid malignancy in patients with Bethesda categories III, IV, and V: a retrospective observational study in a tertiary center. Cureus. 2021;13(7):e16708.","journal-title":"Cureus"},{"issue":"8","key":"1891_CR35","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1089\/thy.2013.0610","volume":"24","author":"M Zou","year":"2014","unstructured":"Zou M, et al. Concomitant RAS, RET\/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 2014;24(8):1256\u201366.","journal-title":"Thyroid"},{"issue":"5","key":"1891_CR36","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.21037\/gs-20-430","volume":"9","author":"FA Rashid","year":"2020","unstructured":"Rashid FA, et al. Prevalence of BRAF(V600E) mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review. Gland Surg. 2020;9(5):1878\u2013900.","journal-title":"Gland Surg"},{"issue":"4","key":"1891_CR37","first-page":"839","volume":"29","author":"KP Hoeflich","year":"2006","unstructured":"Hoeflich KP, et al. Regulation of ERK3\/MAPK6 expression by BRAF. Int J Oncol. 2006;29(4):839\u201349.","journal-title":"Int J Oncol"},{"issue":"6","key":"1891_CR38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1530\/EC-19-0045","volume":"8","author":"G Zhu","year":"2019","unstructured":"Zhu G, et al. Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy. Endocr Connect. 2019;8(6):754\u201363.","journal-title":"Endocr Connect"},{"issue":"28","key":"1891_CR39","doi-asserted-by":"publisher","first-page":"e16343","DOI":"10.1097\/MD.0000000000016343","volume":"98","author":"XJ Li","year":"2019","unstructured":"Li XJ, et al. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules. Medicine (Baltimore). 2019;98(28):e16343.","journal-title":"Medicine (Baltimore)"},{"key":"1891_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-pathol-042220-022304","volume":"17","author":"A Papanicolau-Sengos","year":"2022","unstructured":"Papanicolau-Sengos A, Aldape K. DNA methylation profiling: an emerging paradigm for cancer diagnosis. Annu Rev Pathol. 2022;17:295\u2013321.","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"1891_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40618-018-0922-0","volume":"42","author":"K Zhang","year":"2019","unstructured":"Zhang K, et al. DNA methylation alterations as therapeutic prospects in thyroid cancer. J Endocrinol Invest. 2019;42(4):363\u201370.","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1891_CR42","doi-asserted-by":"publisher","first-page":"710","DOI":"10.4161\/epi.20524","volume":"7","author":"M Brait","year":"2012","unstructured":"Brait M, et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics. 2012;7(7):710\u20139.","journal-title":"Epigenetics"},{"issue":"5","key":"1891_CR43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/MED.0000000000000430","volume":"25","author":"HS Kazaure","year":"2018","unstructured":"Kazaure HS, Roman SA, Sosa JA. The impact of age on thyroid cancer staging. Curr Opin Endocrinol Diabetes Obes. 2018;25(5):330\u20134.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"1891_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12020-020-02207-6","volume":"68","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Thyroid cancer: incidence and mortality trends in China, 2005\u20132015. Endocrine. 2020;68(1):163\u201373.","journal-title":"Endocrine"},{"issue":"2","key":"1891_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.biopha.2011.11.010","volume":"66","author":"S Rajoria","year":"2012","unstructured":"Rajoria S, et al. Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomed Pharmacother. 2012;66(2):151\u20138.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"1891_CR46","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1001\/archoto.2011.194","volume":"137","author":"A Kamat","year":"2011","unstructured":"Kamat A, et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Arch Otolaryngol Head Neck Surg. 2011;137(11):1146\u201353.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"11","key":"1891_CR47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrc1739","volume":"5","author":"JA Ludwig","year":"2005","unstructured":"Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1891_CR48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00428-018-2301-9","volume":"472","author":"G Cserni","year":"2018","unstructured":"Cserni G, et al. The new TNM-based staging of breast cancer. Virchows Arch. 2018;472(5):697\u2013703.","journal-title":"Virchows Arch"},{"issue":"3","key":"1891_CR49","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00405-019-05759-0","volume":"277","author":"HY Kim","year":"2020","unstructured":"Kim HY, et al. Clinical difference between benign and malignant tumors of the hard palate. Eur Arch Otorhinolaryngol. 2020;277(3):903\u20137.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"9","key":"1891_CR50","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jamaoncol.2020.2592","volume":"6","author":"A Patel","year":"2020","unstructured":"Patel A. Benign vs malignant tumors. JAMA Oncol. 2020;6(9):1488.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1891_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.amjmed.2007.07.025","volume":"121","author":"T Kohnlein","year":"2008","unstructured":"Kohnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med. 2008;121(1):3\u20139.","journal-title":"Am J Med"},{"key":"1891_CR52","doi-asserted-by":"publisher","first-page":"104177","DOI":"10.1016\/j.cellimm.2020.104177","volume":"356","author":"R Schuster","year":"2020","unstructured":"Schuster R, et al. Distinct anti-inflammatory properties of alpha1-antitrypsin and corticosteroids reveal unique underlying mechanisms of action. Cell Immunol. 2020;356:104177.","journal-title":"Cell Immunol"},{"issue":"6","key":"1891_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3892\/ol.2020.12141","volume":"20","author":"L Jiang","year":"2020","unstructured":"Jiang L, Hu LG. Serpin peptidase inhibitor clade A member 1-overexpression in gastric cancer promotes tumor progression in vitro and is associated with poor prognosis. Oncol Lett. 2020;20(6):278.","journal-title":"Oncol Lett"},{"issue":"11","key":"1891_CR54","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.3390\/ijms22116079","volume":"22","author":"W Chia-Chun","year":"2021","unstructured":"Chia-Chun W, et al. Identification of fucosylated SERPINA1 as a novel plasma marker for pancreatic cancer using lectin affinity capture coupled with iTRAQ-based quantitative glycoproteomics. Int J Mol Sci. 2021;22(11):6079. https:\/\/doi.org\/10.3390\/ijms22116079.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1891_CR55","doi-asserted-by":"publisher","first-page":"9563","DOI":"10.1038\/s41598-020-66825-w","volume":"10","author":"N Schwarz","year":"2020","unstructured":"Schwarz N, et al. Alpha1-antitrypsin protects lung cancer cells from staurosporine-induced apoptosis: the role of bacterial lipopolysaccharide. Sci Rep. 2020;10(1):9563.","journal-title":"Sci Rep"},{"issue":"1","key":"1891_CR56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1134\/S002689331601012X","volume":"50","author":"M Ljujic","year":"2016","unstructured":"Ljujic M, et al. Alpha-1 antitrypsin affects U0126-induced cytotoxicity in colon cancer cell line (HCT116). Mol Biol (Mosk). 2016;50(1):174\u20138.","journal-title":"Mol Biol (Mosk)"},{"issue":"22","key":"1891_CR57","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, et al. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446\u201356.","journal-title":"Cancer"},{"key":"1891_CR58","doi-asserted-by":"publisher","first-page":"e14996","DOI":"10.7717\/peerj.14996","volume":"11","author":"J Liang","year":"2023","unstructured":"Liang J, et al. HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6\/Akt pathway. PeerJ. 2023;11:e14996.","journal-title":"PeerJ"},{"key":"1891_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.imlet.2022.04.004","volume":"246","author":"L Chen","year":"2022","unstructured":"Chen L, Zhuo D, Yuan H. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K\/AKT\/mTOR signaling pathway. Immunol Lett. 2022;246:10\u20137.","journal-title":"Immunol Lett"},{"issue":"1","key":"1891_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12967-021-03226-1","volume":"20","author":"T Zheng","year":"2022","unstructured":"Zheng T, et al. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K\/AKT pathway in papillary thyroid carcinoma. J Transl Med. 2022;20(1):20.","journal-title":"J Transl Med"},{"key":"1891_CR61","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.11839","author":"M Zhang","year":"2021","unstructured":"Zhang M, et al. miR\u2011653\u20115p suppresses the growth and migration of breast cancer cells by targeting MAPK6. Mol Med Rep. 2021. https:\/\/doi.org\/10.3892\/mmr.2021.11839.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1891_CR62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7150\/ijbs.63388","volume":"18","author":"Y Huang","year":"2022","unstructured":"Huang Y, et al. Rab31 promotes the invasion and metastasis of cervical cancer cells by inhibiting MAPK6 degradation. Int J Biol Sci. 2022;18(1):112\u201323.","journal-title":"Int J Biol Sci"},{"key":"1891_CR63","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu PD. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01891-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:03:00Z","timestamp":1748502180000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01891-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1891"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01891-3","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"86"}}